A collaboration with the FDA: How Flatiron real-world evidence provides actionable insights

View the ASCO 2017 poster

The clinico-genomic database: Advance personalized medicine with a revolutionary discovery tool

View the product summary

How drugs go viral: Flatiron's real-world data show how uptake happens

View The Cancer Letter article

Integrated at the source. Expanded with linked data sets.

  • Derived from the EHRs of over 265 community clinics and academic institutions at over 800 unique sites of care.
  • The largest and highest quality source for real-world evidence in oncology – includes both structured and unstructured data.
  • Access longitudinal clinical data, with the ability to link to external data sources like genomics, mortality and closed claims.

Designed to meet the most rigorous quality standards for RWE.

Technology-Enabled Abstraction

Patent-pending abstraction process carefully augments human expertise with machine learning and other technology-enabled optimizations.

Data Quality Control

Thorough quality assurance and complete data provenance for every data point generated.

Regulatory Collaborations

Active collaborations with the FDA and NCI to define the requirements and uses for regulatory grade RWE.

This is a complete breakthrough, because this type of data—previously used for publication, some payer support, and outcomes research—has never been used for regulatory support.

Maria Koehler, MD, PhD — The Cancer Letter — June 9, 2017
Vice President, Oncology Strategy, Innovation & Collaborations, Pfizer Oncology

Let us tell you more.

We will email you to start the conversation.

Thank you. We'll be in touch shortly.